Evaluation of mutagenicity, genotoxicity and chronic toxicity of antiviral drug imidazolyl ethanamide pentandioic acid in <i>in vitro</i> and <i>in vivo</i> test systems-Reference-Cited by-同舟云学术

Evaluation of mutagenicity, genotoxicity and chronic toxicity of antiviral drug imidazolyl ethanamide pentandioic acid in in vitro and in vivo test systems

Published:2021-11-02 Issue:5 Volume:98 Page:548-557
ISSN:2686-7613
Container-title:Journal of microbiology, epidemiology and immunobiology
language:
Short-container-title:Zhurnal mikrobiologii, èpidemiologii i immunobiologii

Author:

Jain E. A.¹^ORCID,Pleimes D.²^ORCID,Globenko A. A.¹^ORCID

Affiliation:

1. JSC Valenta Pharm Pharmaceutical Company

2. Myelo Therapeutics GmbH

Abstract

Introduction. The antiviral properties of imidazolyl ethanamide pentandioic acid (IPA), the active compound of the drug product, has been proven in various experimental models. However, the literature data on the toxicological properties of IPA are limited.Purpose. To evaluate mutagenic and genotoxic properties in in vitro and in vivo models, as well as to study the toxicity of IPA following chronic oral administration to rats and dogs.Materials and methods. Mutagenic and genotoxic properties of IPA were assessed using the Ames test, the test of chromosomal aberrations in human lymphocytes, and the micronucleus test in rats. The chronic toxicity of IPA was studied in Sprague Dawley rats and beagle dogs of both sexes, to which IPA was administered orally at doses of 30-300 mg/kg/day for 26 and 39 weeks, respectively.Results and discussion. In the Ames test, the addition of IPA up to the maximum dose (5000 mcg/plate) did not result in the increase in the number of revertant colonies. At a concentration of up to 5000 mcg/ml, IPA did not cause chromosomal aberrations in human leukocytes. At doses doses ≤ 2000 mg/kg, IPA did not increase the amount of micronuclei in the bone marrow of rats. In chronic experiments, animals tolerated the administration of IPA well: the dose without an observed effect (NOEL) for rats and dogs was 300 mg/kg/day.Conclusion. IPA did not show mutagenic and genotoxic properties in standard in vitro and in vivo tests. With chronic oral administration to rats and dogs, NOEL IPA equal to 300 mg/kg/day provided a systemic exposure that was 8-10 and 41-65 times higher than that in humans, respectively. The results obtained allow us to consider the safety profile of the prolonged use in humans as favorable.

Publisher

Central Research Institute for Epidemiology

Subject

General Medicine

Reference23 articles.

1. Zarubaev V.V., Garshinina A.V., Kalinina N.A., Shtro A.A., Belyaevskaya S.V., Slita A.V., et al. Activity of ingavirin (6-[2-(1H-Imidazol-4-yl)ethylamino]-5-oxo-hexanoic acid) against human respiratory viruses in in vivo experiments. Pharma ceuticals (Basel). 2011; 4(12): 1518-34. https://doi.org/10.3390/ph4121518

2. Malik I., Kovac G., Padrtova T., Hudecova L. Ingavirin might be a promising agent to combat Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2). Ceska Slov. Farm. 2020; 69(3): 107-11.

3. Shishkina L.N., Nebol'sin V.E., Kabanov A.S., Skarnovich M.O., Erdyneeva U.B., Mazurkova N.A., et al. In vitro efficacy of Ingavirin against the pandemic influenza virus A(H1N1/09)v. Antibiotiki i khimioterapiya. 2010; 55(3-4): 12-6. (in Russian)

4. Loginova S.Ya., Borisevich S.V., Semenova I.A., Borisevich G.V., Maksimov V.A., Bondarev V.P., et al. In vitro investigation of Ingavirin efficacy against influenza B virus. Antibiotiki i khimioterapiya. 2009; 54(7-8): 13-5. (in Russian)

5. Loginova S.Ya., Borisevich S.V., Shchukina V.N., Lykov M.V., Borisevich G.V., Bondarev V.P., et al. Study of Ingavirin antiviral activity against Mexican pandemic influenza virus A/H1N1/2009 in vitro and in vivo. Antibiotiki i khimioterapiya. 2010; 55(11-12): 17-21. (in Russian)